GENPF (Genix Pharmaceuticals) Operating Income: $-0.09 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genix Pharmaceuticals Operating Income?

Genix Pharmaceuticals GENPF Operating Income is $-0.09 Mil as of Apr. 2026. The stock has 3 warning signs investors should review.

Genix Pharmaceuticals's Operating Income for the three months ended in Apr. 2026 was $-0.02 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.09 Mil.

Warning Sign:

Genix Pharmaceuticals Corp has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Genix Pharmaceuticals's Operating Income for the three months ended in Apr. 2026 was $-0.02 Mil. Genix Pharmaceuticals's Revenue for the three months ended in Apr. 2026 was $0.00 Mil. Therefore, Genix Pharmaceuticals's Operating Margin % for the quarter that ended in Apr. 2026 was %.

Genix Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genix Pharmaceuticals's annualized ROC % for the quarter that ended in Apr. 2026 was -8.13%. Genix Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was %.

Genix Pharmaceuticals  (OTCPK:GENPF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genix Pharmaceuticals's annualized ROC % for the quarter that ended in Apr. 2026 is calculated as:

ROC % (Q: Apr. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2026 ) + Invested Capital (Q: Apr. 2026 ))/ count )
=-0.08 * ( 1 - 0% )/( (0.956 + 1.012)/ 2 )
=-0.08/0.984
=-8.13 %

where

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.025 - 0.138 - ( 0.009 - max(0, 1.094 - 0.025+0.009))
=0.956

Invested Capital(Q: Apr. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.024 - 0.139 - ( 0.008 - max(0, 1.151 - 0.024+0.008))
=1.012

Note: The Operating Income data used here is four times the quarterly (Apr. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Genix Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2026  Q: Apr. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.084/( ( (0 + max(-0.294, 0)) + (0 + max(-0.296, 0)) )/ 2 )
=-0.084/( ( 0 + 0 )/ 2 )
=-0.084/0
= %

where Working Capital is:

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0 + 0.015) - (0.138 + 0 + 0.172)
=-0.294

Working Capital(Q: Apr. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.002 + 0 + 0.014) - (0.139 + 0 + 0.173)
=-0.296

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Genix Pharmaceuticals's Operating Margin % for the quarter that ended in Apr. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=-0.02/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Genix Pharmaceuticals Operating Income Related Terms

Genix Pharmaceuticals Operating Income Historical Data

* Premium members only.

The historical data trend for Genix Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genix Pharmaceuticals Operating Income Chart

Genix Pharmaceuticals Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.33 -0.75 -0.64 -0.18 -0.11

Genix Pharmaceuticals Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.02 -0.02 -0.02

Genix Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-0.09 Mil mean?
Genix Pharmaceuticals (GENPF) has a Operating Income of $-0.09 Mil as of Apr. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Genix Pharmaceuticals and its competitors.
Is Genix Pharmaceuticals' Operating Income too high?
Genix Pharmaceuticals' current Operating Income is $-0.09 Mil.
How does Genix Pharmaceuticals' Operating Income compare to ZTS and UTHR?
Genix Pharmaceuticals' Operating Income of $-0.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Genix Pharmaceuticals and its competitors. Genix Pharmaceuticals's current Operating Income is $-0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current Operating Income of $-0.09 Mil. The current Operating Income is $-0.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current Operating Income is $-0.09 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genix Pharmaceuticals Business Description

Other Exchanges GENX:Canada
Address 1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.